drugset / Trial / NCT05166967
Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
Phase 3
Completed
204 enrolled
Chinese PLA General Hospital
Peking University People's Hospital, Peking University Institute of Hematology · collabThe First Affiliated Hospital of Zhengzhou University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-02-16
- Completion
- 2025-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 13 mg/kg | Intravenous |